Evidence for the presence of chronic inflammation during peritoneal dialysis: Therapeutic implications

Peritoneal Dialysis International

Volumn 17, Issue SUPPL. 2, 1997, Pages

  Breborowicz, Andrzej ^a   Oreopoulos, Dimitrios G ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Fibrinolysis; Inflammation

Indexed keywords

DIALYSIS FLUID;

CHRONIC INFLAMMATION; CONFERENCE PAPER; HOMEOSTASIS; LEUKOCYTE; MESOTHELIUM CELL; PATHOGENESIS; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEUM; PERITONEUM CELL; PRIORITY JOURNAL;

EID: 0030783635     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089701702s07     Document Type: Conference Paper

References (55)

1. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif 1989; 7:74-85.
2. Heimburger O, Waniewski J, Weryñski A, et al. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495-506.
3. Liberek T, Topley N, Jörres A, et al. Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration. J Am Soc Nephrol 1993; 3:1508-15.
4. Jörres A, Gahl GM, Frei U. In vitro studies on the effect of dialysis solutions on peritoneal leukocytes. Perit Dial Int 1995; 15:841-6.
5. Dawnay A. Advanced glycation end products in peritoneal dialysis. Perit Dial Int 1996; 16:S50-3.
6. Yamada K, Miyahara Y, Hamaguchi K, et al. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 1994; 42:354-61.
7. Beelen RHJ, van der Meulen J, Verbrugh HA, et al. CAPD, a permanent state of peritonitis: a study on peroxidase activity. In: Maher JF, Winchester JF, eds. Frontiers in Peritoneal Dialysis. New York: Field, Rich, 1986; 524-30.
8. Brulez HFH, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 1995; 15:824-34.
9. Dobbie JW. Durability of the peritoneal membrane. Perit Dial Int 1995; 15:S87-92.
10. Breborowicz A, Martis L, Oreopoulos DG. Changes in biocompatibility of dialysis fluid during its dwell in the peritoneal cavity. Perit Dial Int 1995; 15:152-170.
11. Bos HJ, Meyer F, Veld JC, et al. Peritoneal dialysis fluid induces a change of mononuclear phagocyte properties. Kidney Int 1989; 36:20-6.
12. Dobbie JW. Serositis: comparative analysis of histological findings and pathogenetic mechanisms in nonbacterial serosal inflammation.Perit Dial Int 1993; 13:256-69.
13. Chan MK, Chow L, Lam SS, et al. Peritoneal eosinophilia in patients on continuous ambulatory peritoneal dialysis: a prospective study. Am J Kidney Dis 1988; 11:180-3.
14. Davies SJ, Suassuna J, Ogg CS, et al. Activation of immunocompetent cells in the peritoneum of patients treated with CAPD. Kidney Int 1989; 36:661-8.
15. Betjes MGH, Tuk CW, Struijk DG, et al. Immuno-effector characteristics of peritoneal cells during CAPD treatment: A longitudinal study. Kidney Int 1993; 43:641-8.
16. Libetta C, De Nicola L, Rampino T, et al. Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 1996; 49:506-11.
17. McGregor SJ, Topley N, Jörres A, et al. Longitudinal evaluation of peritoneal macrophage function and activation during CAPD: Maturity, cytokine synthesis and arachidonic acid metabolism. Kidney Int 1996; 49:525-33.
18. Bos HJ, Struijk DG, Tuk CW, et al. Peritoneal dialysis induces a local sterile inflammatory state and the mesothelial cells in the effluent are related to the bacterial peritonitis incidence. Nephron 1991; 59:508-9.
19. Goldman M, Vandenabeele P, Moulart J, et al. Intraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis. Nephron 1990; 56:277-80.
20. Betjes MGH, Visser CE, Zemel D, et al. Intraperitoneal interleukin-8 and neutrophil influx in the initial phase of a CAPD peritonitis. Perit Dial Int 1996; 16:385-92.
21. Snitkoff G, Bailie GR, Eisele G. Interleukin, endotoxin and tumor necrosis factor in CAPD dialysate. Perit Dial Int 1995; 15:279-80.
22. Mariano F, Tetta C, Montrucchio G, et al. Role of alpha1-proteinase inhibitor in restraining peritoneal inflammation in CAPD patients. Kidney Int 1992; 42:735-42.
23. Zemel D, Imholz ALT, de Waart DR, et al. Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46:1422-30.
24. Taylor JE, Scott N, Bridges A, et al. Lipid peroxidation and antioxidants in continuous ambulatory dialysis patients. Perit Dial Int 1992; 12:252-6.
25. Breborowicz A, Karon J, Korybalska K, et al. Functional properties of mesothelial cells after prolonged exposure to dialysate effluent. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1995; 11:15-8.
26. Selgas R, Lopez-Rivas A, Miranda B, et al. Characterisation of the mitogenic-induced capacity of peritoneal effluent on human and mice fibroblasts and culture. Nephrol Dial Transpl 1991; 6:44-50.
27. Breborowicz A, Korybalska K, Grzybowski A, et al. Synthesis of hyaluronic acid by human peritoneal mesothelial cells: effect of cytokines and dialysate. Perit Dial Int 1996; 16:374-8.
28. Freiman JP, Graham DJ, Reed TG, et al. Chemical peritonitis following the intraperitoneal administration of vancomycin. Perit Dial Int 1992; 12:57-60.
29. Junor BJR, Briggs JD, Forwell MA, et al. Sclerosing peritonitis - the contribution of chlorhexidine in alcohol. Perit Dial Bull 1985; 5:101-4.
30. Fracasso A, Coli U, Landini S, et al. Peritoneal sclerosis. Role of plasticizers. Trans Am Soc Artif Intern Organs 1987; XXXIII:676-82.
31. Mettang T, Thomas S, Kiefer T, et al. The fate of leached di(2-ethylhexyl)phtalate in patients undergoing CAPD treatment. Perit Dial Int 1996; 16:58-62.
32. Prowant B, Nolph K, Ryan L, et al. Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience. Nephron 1986; 43:105-9.
33. Shaldon S, Koch KM, Quellhorst E, et al. Pathogenesis of sclerosing peritonitis in CAPD. Trans Am Soc Artif Intern Organs 1984; 30:193-4.
34. Vlassara H, Brownlee M, Manogue KR, et al. Cachectin/ TNF and II-1 induced by glucose-modified proteins: Role in normal tissue remodelling. Science 1998; 240:1546-8.
35. Vlassara H. Advanced Nonenzymatic Tissue Glycosylation: cell-mediated interactions implicated in the complications associated with diabetes and aging. Blood Purif 1990; 8:223-32.
36. Haussinger D, Lang F, Gerok W. Regulation of cell function by the cellular hydration state. Am J Physiol 1994; 267:E343-55.
37. Breborowicz A, Rodela H, Karon J, et al. In vitro simulation of the effect of peritoneal dialysis solution on mesothelial cells. Am J Kidney Dis. In press.
38. van Hinsbergh VWM, Kooistra T, Scheffer MA, et al. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. Blood 1990; 75:1490-7.
39. Gries E, Paar D, Graben N, et al. Intraperitoneal fibrin-formation and its inhibition in CAPD. Clin Nephrol 1986; 26:209-12.
40. Sitter T, Spannagl M, Schiffl H, et al. Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells. Nephrol Dial Transpl 1995; 10:677-83.
41. Slater ND, Cope GH, Raftery AT. Peritoneal plasminogen activator activity after chronic exposure to dialysis fluid. Perit Dial Int 1992; 12:262-3.
42. Ho-Dac-Pannekeet M, Krediet R. Inflammatory changes in vivo during CAPD: What can the effluent tell us? Kidney Int 1996; 50:S12-6.
43. Dobbie JW. Pathogenesis of Peritoneal Fibrosing Syndromes (Sclerosing Peritonitis) in Peritoneal Dialysis. Perit Dial Int 1992; 12:14-27.
44. Friedman EA. Will pimagidine improve survival of diabetics on dialysis? Nephrol Dial Transpl 1996; 11:1524-7.
45. Keane WF, Vas SI. Peritonitis. In: Gokal R, Nolph KG, eds. The textbook of peritoneal dialysis. Dordrecht/ Boston/London: Kluwer Academic Publishers, 1994; 473-501.
46. Breborowicz A, Wieczorowska K, Martis L, et al. Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron 1994;67:346-50.
47. Bazzato G, Fracasso A, Re G, et al. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet 1995; 346:740-1.
48. Wieczorowska K, Breborowicz A, Martis L, et al. Protective effect of hyaluronic acid against peritoneal injury. Perit Dial Int 1995; 15:81-3.
49. Yung S, Coles GA, Williams JD, et al. The source and possible significance of hyaluronan in the peritoneal cavity. Kidney Int 1994; 46:527-33.
50. Lipkin GW, Forbes MA, Cooper EH, et al. Hyaluronic acid metabolism and its clinical significance in patients treated by continuous ambulatory peritoneal dialysis. Nephrol Dial Transpl 1993; 8:357-60.
51. Forrester JV, Balazs EA. Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology 1980; 40:435-46.
52. Suzuki Y, Yamaguchi T. Effects of hyaluronic acid on macrophage phagocytosis and active oxygen release. Agents Action 1993; 38:32-7.
53. Akatsuka M, Yamamoto Y, Tobetto K, et al. Suppressive effects of hyaluronic acid on elastase release from rat peritoneal leukocytes. J Pharm Pharmacol 19931; 45:110-4.
54. Weigel PH, Fuller GM, LeBoeuf RD. A model for the role of hyaluronic acid and fibrin in early events during the inflammatory response and wound healing. J Theor Biol 1986; 119:219-26.
55. Nagy JA. Peritoneal membrane morphology and function. Kidney Int 1996; 50:S2-11.